Valproate: Clinical Pharmacological Profile

  title={Valproate: Clinical Pharmacological Profile},
  author={C. Bowden and Vivek Singh},

Topics from this paper

Predictive animal models of mania: hits, misses and future directions
A review of pharmacological, environmental and genetic manipulations developed to test the efficacy of therapeutics in animal models of mania and the predictive validity of these models is discussed in the context of differentiating drugs that succeed or fail to meet criteria as approved mania treatments. Expand
Bipolar Disorder: Diagnosis, Pathophysiology and Therapy
Bipolar disorder is a mental illness that causes dramatic shifts in a person’s mood, energy and ability to think clearly and often involves a combination of medications and psychotherapy. Expand


Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study.
Divalproex appeared to be an effective treatment for acute nonrefractory bipolar depression, which is consistent with previous small randomized studies, and some evidence of benefit in the depressive mixed state was observed. Expand
A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.
The results suggest that quetiapine is at least as effective as divalproex in the treatment of acute manic symptoms associated with adolescent bipolar disorder; however, a quicker reduction of manic symptoms may occur with quetuapine as compared with divalProex. Expand
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.
Divalproex ER is effective and safe for the treatment of mania episodes in bipolar I patients and five of the 11 MRS items improved significantly more in patients receiving divalProex ER than placebo. Expand
Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.
The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of Valproate for best response in acute mania is above 94 microg/ml. Expand
Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder
Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism and Prospective studies are needed to elucidate risk factors for development of PCOS on valproate. Expand
A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder.
The hypothesis that divalproex is more effective than lithium in the long-term management of rapid-cycling bipolar disorder is not supported by these data, and preliminary data suggest highly recurrent refractory depression may be the hallmark of rapidly-cycled bipolar disorder. Expand
Atypical antipsychotics for bipolar disorder.
  • L. Yatham
  • Medicine
  • The Psychiatric clinics of North America
  • 2005
Overall, the atypical antipsychotic agents as a group represent an effective and relatively safe addition to the armamentarium for the treatment of bipolar disorder. Expand
Divalproex in the treatment of bipolar depression: a placebo-controlled study.
These pilot results indicate that divalproex is effective in reducing the symptoms of depression and anxiety in bipolar I, depressed phase, and support the need to perform a larger, multisite study of divalProex treatment for bipolar depression. Expand
Divalproex sodium for pediatric mixed mania: a 6-month prospective trial.
Evidence is provided for the effectiveness and safety of DVPX in the treatment of pediatric mixed mania over a 6-month period and placebo-controlled, randomized trials involving larger samples will ultimately shed light on the efficacy of this agent. Expand
Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder.
DVPX was not found to be superior to Li+ as maintenance treatment in youths who stabilized on combination Li+ and DVPX pharmacotherapy in youths diagnosed with bipolar I or II disorder. Expand